arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Climb Bio, Inc.

CLYM
$14.01 ▲ +0.03 (+0.21%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
26 Visible periods
19 Metrics
Peer-ranked Benchmarks
Price Chart
32
Health
Poor
Bearish
auto_awesome

Analytical Summary

Climb Bio, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $955.6M
Dividend Yield
Revenue Growth
Op. Margin
ROIC -8.1%
FCF / Share $-0.21
Trailing P/E
Price / Book 4.5x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

26-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-13.72M
↑ +34.0%
FCF / Share Free cash flow per share
$-0.21
↑ +7.9%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
20
Cash Quality
61

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 26 quarters